(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 June 2009 (18.06.2009)

PCT

(10) International Publication Number
WO 2009/074796 A3

(51) **International Patent Classification**:
A61K 38/18 (2006.01)

(21) **International Application Number**:
PCT/GB2008/004078

(22) **International Filing Date**:
11 December 2008 (11.12.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
0724204.3 12 December 2007 (12.12.2007) GB

(71) **Applicant** *(for all designated States except US)*: **RENOVO LIMITED** [GB/GB]; Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **FERGUSON, Mark, William, James** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **O'KANE, Sharon** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **OCCLESTON, Nicholas** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **GOLDSPINK, Nicholas** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **NIELD, Kerry** [GB/GB]; Renovoto Limited, Incubator Building, 48 Grafton Street, Manchestr M13 9XX (GB). **SATTAR, Abdul** [GB/GB]; Renovoto Limited, Incubator Building, 48 Grafton Street, Manchestr M13 9XX (GB). **BUSH, James** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB).

(74) **Agents**: **ARMSTRONG, Iain, Cheshire** et al.; Marks & Clerk LLP, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) **Date of publication of the international search report**:
15 October 2009

(15) **Information about Correction**:

Previous Correction:
see Notice of 20 August 2009

(54) **Title**: INHIBITION OF SCARRING USING TGF-BETA 3

(57) **Abstract**: The invention provides new methods of treatment using TGF- β 3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

WO 2009/074796 A3